Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 10
Submit an article Journal homepage
51
Views
18
CrossRef citations to date
0
Altmetric
Miscellaneous

Recent advances in the cannabinoids

Phillip Cowley Organon Laboratories Ltd, Newhouse, Lanarkshire, ML1 5SH, Scotland, UK. [email protected]
&
Julia Adam Organon Laboratories Ltd, Newhouse, Lanarkshire, ML1 5SH, Scotland, UK. [email protected]
Pages 1475-1489 | Published online: 25 Feb 2005

Bibliography

  • GOYA P, JAGEROVIC N: Recent advances in cannabinoid receptor agonists and antagonists. Exp. Opin. Ther. Patents (2000) 10:1529–1538.
  • •Preceeding review article in this journal.
  • HOWLETT AC, BARTH F, BONNER TI et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. (2002) 54:161–202.
  • ••An excellent review giving the current state of the art in cannabinoid pharmacology.
  • MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561–564.
  • SHIRE D, CARILLON C, KAGHAD M et al.: An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. Biol. Chem. (1995) 270:3726–3731.
  • MUNRO S, THOMAS KL, ABU SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61–65.
  • DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
  • MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochern. Pharmacol (1995) 50:83–90.
  • SUGIURA T, KONDO S, SUKAGAWA A et al: 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in the brain. Biochem. Biophys. Res. Commun. (1995) 215:89–97.
  • HANUS L, ABU-LAFI S, FRIDE S et al: 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA (2001) 98:3662–3665.
  • PORTER AC, SAUER J-M, KNIERMAN MD et al.: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Pharmacol. Exp. Thar. (2002) 301:1020–1024.
  • COMPTON DR, JOHNSON MR, MELVIN LS, MARTIN BR: Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. " Pharmacol. Exp. Thar. (1992) 260:201–209.
  • CALIGNANO A, LA RANA G, GIUFFRIDA A, PIOMELLI D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 394:277–281.
  • CALIGNANO A, LA RANA G, PIOMELLI D: Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Euc.f. Pharmacol. (2001) 419:191–198.
  • DI MARZO V, BREIVOGEL CS, TAO Q et al.: Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. " Neurochem. (2000) 75:2434–2444.
  • BREIVOGEL CS, GRIFFIN G, DI MARZO V, MARTIN BR: Evidence for a new G-protein coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. (2001) 60:155–163.
  • JARAI Z, WAGNER JA, VARGA K et al: Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sd. USA (1999) 96:14136–14142.
  • SHOHAMI E, MECHOULAM R: Dexanabinol (HU-211): a non-psychotropic cannabinoid with neuroprotective properties. Drug Dev. Res (2000) 50:211–215.
  • MARSICANO G, MOOSMANN B, HERMANN H, LUTZ B, BEHL C: Neuroprotective properties of cannabinoids against oxidative stress:role of cannabinoid receptor CB1. Neurochem. (2002) 80:448–456.
  • MECHOULAM R, PANIKASHVILI D, SHOHAMI E: Cannabinoids and brain injury: therapeutic implications. Trends M Molecular Medicine (2002) 8:58–61.
  • GLASS M: The role of cannabinoids in neurodegenerative diseases. Prog. Nemo-psychopharmacol. it Biol. Psychiat. (2001) 25:743–765.
  • HUFFMAN JW: The search for selective ligands for the CB2 receptor. Current Pharmaceutical Design (2000) 6:1323–1337.
  • HANUS L, BREUER A, TCHILIBON S, SHILOAH S, GOLDENBERG D et al.: HU-308:a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Nati Acad. Sci. USA (1999) 96:14228–14233.
  • HUFFMAN JW, JOYNER HH, LEE MD, JORDAN RD, PENNINGTON WT: Synthesis of both enantiomers of nabilone from a common intermediate. Enantiodivergent synthesis of cannabinoids. J. Org. Chem. (1991) 56:2081–2086.
  • DRAKE DJ, JENSEN RS, BUSCH PETERSEN J et al.: Classical/non-classical hybrid cannabinoids:southern aliphatic chain-functionalised C-6I3 methyl, ethyl and propyl analogues. j. Med. Chem. (1998) 41:3596–3608.
  • GALVE-ROPERH I, SANCHEZ C, CORTES ML, GOMEZ DEL PULGAR T, IZQUIERDO M, GUZMAN M: Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine (2000) 6:313–319.
  • DE PETROCELLIS L, MELCK D, PALMISANO A et al.: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Nati Acad. Sci. USA (1998) 95:8375–8380.
  • RECHT, LD et al.: Antitumour effects of ajulemic acid (CT-3), a synthetic non-psychoactive cannabinoid. Biochem. Pharmacol. (2001) 62:755–763.
  • MECHOULAM R, RHEE M-H, VOGEL Z et al.: Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase." Med. Chem. (1997) 40:3228–3233.
  • BURSTEIN, SH: The cannabinoid acids: non-psychoactive derivatives with therapeutic potential. Pharmacol. Ther. (1999) 82:87–96.
  • BISOGNO T, HANUS L, DE PETROCELLIS L et al.: Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. .1. Pharmacol. (2001) 134:845–852.
  • BARTH F, RINALDI-CARMONA M: The development of cannabinoid antagonists. Current Med. Chem. (1999) 6:745–755.
  • RINALDI-CARMONA M, BARTH F, HEAULME M et al.: 5R141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240–244.
  • NAKAMURA-PALACIOS EM, MOERSCHBAECHER JM, BARKER LA: The pharmacology of 5R141716A: a review. CNS Drug Reviews (1999) 5:43–58.
  • RINALDI-CARMONA M, BARTH F, MILLAN J et al: 5R144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. I Pharmacol. Exp. Thei: (1998) 284:644–650.
  • LE FUR G, ARNONE M, RINALDI CARMONA M, BARTH F, HESHMATI H: 5R141716A, a selective antagonist of CB1 receptors and obesity. International Cannabinoid Research Society Symposium on the Cannabinoids. San Lorenzo de El Escorial, Spain (2001).
  • HESHMATI HM, CAPLAIN H, BELLISLE F, MOSSE M, FAUVEAU C, LE FUR G: 5R141716A, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake and body weight in overweight or obese men. The North American Association for the study of Obesio Annual Meeting. Quebec Cioi, Canada (2001). Supp1.3 069.
  • THOMAS BF, GILLIAM AF, BURCH DF, ROCHE MJ, SELTZMAN HH: Comparitive receptor binding analyses of cannabinoid agonists and antagonists." Pharmacol. Exp. Thar. (1998) 285:285–292.
  • WILEY JL, JEFFERSON RG, GRIER MC, MAHADEVAN A, RAZDAN RK, MARTIN BR: Novel pyrazole cannabinoids:insights into CB1 receptor recognition and activation.' Pharmacol. Exp. Thei: (2001) 296:1013–1022.
  • FRANCISCO MEY, SELTZMAN HH, GILLIAM AF et al.: Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB1 receptor antagonist N-(piperidinyl) 5 (4 chloropheny1)-1-(2,4-dichloropheny1)-4-methyl-1H-pyrazole-3-carboxamide (512141716). " Med. Chem. (2002) 45:2708–2719.
  • OOMS F, WOUTERS J, OSCARI O et al: Exploration of the pharmacophore of 3-alkyl-5-arylimidazolinediones as new CB1 cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity and molecular modelling. I Med. Chem. (2002) 45:1748–1756.
  • MARTIN D, NEAR SL: Protective effect of the interleukin-1 receptor antagonist (IL-lra) on experimental allergic enchephalomyelitis in rats. Neuroimmunol (1995) 61:241–245.
  • GERRITSE K, LAMAN JD, NOELLE RJ et al.: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA (1996) 93:2499–2504.
  • CORRIGALL WA, COEN KM: Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (1989) 99:473–478.
  • IWAMURA H, SUZUKI H, UEDA Y, KAYA T, INABA T: In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. I Pharmacol Exp. Ther. (2001) 296:420–425.
  • PIOMELLI D, GIUFFRIDA A, CALIGNANO A, RODRIGUEZ DE FONCESCA F: The endocannabinoid system as a target for therapeutic drugs. TIPS (2000) 21:218–224.
  • DI MARZO V, BISOGNO T, DE PETROCELLIS L: Endocannabinoids:new targets for drug development. Current Pharmaceutical Design (2000) 6:1361–1380.
  • DI MARZO V, DE PETROCELLIS L, BISOGNO T: Endoeannabinoids Part I: molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors. Emerging Therapeutic Targets (2001) 5:241–265.
  • ••The first part of an excellent series of reviewarticles covering all aspects of the endocannabinoid system.
  • DI MARZO V, BISOGNO T, DE PETROCELLIS L: Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs. Emerging Therapeutic Targets (2001) 5:349–362.
  • ••Part two of the above review series.
  • DI MARZO V, MATIAS I, DE PETROCELLIS L: Endoeannabinoids Part III: diseases of peripheral organs involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs. Emerging Therapeutic Targets(2002) 6:335–347.
  • ••Part three of the above review series.
  • WILSON RI, NICOLL RA: Endocannabinoid signalling in the brain. Science (2002) 296:678–682.
  • ••Describes current understanding of the role of endocannabinoids in the brain and evidence for retrograde signalling within the system.
  • UEDA N, PUFFENBARGER RA, YAMAMOTO S, DEUTSCH DG: The fatty acid amide hydrolase. Chem. Phys. Lipids (2000) 108:107–121.
  • FOWLER CJ, JONSSON K-0, TIGER G: Fatty acid amide hydrolase: biochemistry, pharmacology and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonylglycerol, palmitoylethanolamide and oleamide. Biochem. Pharmacol (2001) 62:517–526.
  • MARTIN BR, BELETSKAYA I, PATRICK G et al.: Cannabinoid properties of methylfluorophosphonate analogs. Pharmacol Exp. Ther (2000) 294:1209–1218.
  • BOGER DL, MIYAUCHI H, HEDRICK MP: a-Keto heterocycle inhibitors of fatty acid amide hydrolase:carbonyl group modification and a-substitution. Bioorg. Med. Chem. Lett. (2001) 11:1517–1520.
  • GLASER ST, STUDHOLME KM, FATADE F, YAZULLA S, ABUMRAD N, DEUTSCH DG: Is there an anandamide transporter? International Cannabinoid Research Society 1 th Annual Symposium on the Cannabinoids. Pacific Grove, CA, USA (2002).
  • BELTRAMO M, STELLA N, CALIGNANO A, LIN SY, MAKRIYANNIS A, PIOMELLI D: Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 277:1094–1097.
  • DI MARZO V, BREIVOGEL C, BISOGNO T et al.: Neurobehavioural activity in mice of N-vanillyl-arachidonyl-amide. Eur. Pharmacol (2000) 406:363–374.

Websites

  • http://www.indevus.com/ Indevus Pharmaceuticals, Inc. Press Release, 01 July 2002.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.